Efficacy of Liraglutide Versus Gliclazide in Treatment of Patients with Type II Diabetes Mellitus: Systematic Review and Meta-Analysis

Abstract

Background: Type 2 diabetes mellitus (T2DM) trig- gers long-lasting and progressive metabolic disorders, causing a severe health issue resulting in several high pre- dominance and dangerous complications. Liraglutide is a glucagon-like peptide-1 (GLP-1), while gliclazide is an oral antihyperglycemic agent. Objectives: To measure the efficacy of gliclazide and liraglutide on T2DM patients. Methods: We performed systematic reviews and meta- analyses by searching two databases, PubMed and Web of Science (WOS), for relevant studies published in the lit- erature during May 2021. We included clinical trials and observational studies and extracted the patients’ base- line characteristics and outcomes. We used the Cochrane Handbook of Systematic Reviews of Interventions and the Newcastle Ottawa scale to assess the included stud- ies’ quality. The statistical analysis was performed by STATA Version 16. Results: Our meta-analysis included three studies (two clinical trials and one observational study) with 137 participants, 71 in the gliclazide and 66 in the liraglu- tide groups. Gliclazide had a non-significant reduction of glycated hemoglobin (HbA1c) compared to liraglu- tide (mean difference [MD] 0.53; 95% CI -0.01, 1.07; P = 0.06). Gliclazide had a non-significant decreasing of body weight compared to liraglutide (standardized mean difference [SMD] 0.32; 95% CI -0.02, 1.07; P = 0.06). Gli- clazide had a non-significant decreasing of low-density lipoprotein cholesterol (LDL-C) and high-density lipopro- tein cholesterol (HDL-C) compared to liraglutide (SMD - 0.11; 95% CI -0.45, 0.23; P = 0.53) and (MD -0.02; 95% CI -0.15, 0.10; P = 0.7). Conclusions: Liraglutide is more effective in reducing HbA1c, body weight LDL-C, and HDL-C than gliclazide. https://doi.org/10.1016/j.ahj.2022.10.016